EUVIMEDScopri EUVIMED
Open access · CC BY-NC 4.0

Blockade of cannabinoid CB 1 receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy

Océane Pointeau iD, Awa Isma Ba, Audrey Geissler, Romain Barbosa, Abhishek Basu, Arif Muhammad, Marina Nivot, Maéva Loriot, Julia Leemput, Patricia Passilly-Degrace, Sébastien Causse iD, Laurent Demizieux and 9 more

British Journal of Pharmacology · 2025-11 · 182 (21) · 5355-5377

DOI: 10.1111/bph.70118 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2025-07-11. Written by Océane Pointeau and 20 co-authors. Institution: Université Bourgogne Europe, INSERM, Center for Translation and Molecular medicine (CTM), Team PAthophysiology of DYSlipidemia (PADYS), Dijon, France. Major MEDLINE topics: Diabetic Nephropathies, Sodium-Glucose Transporter 2 Inhibitors, Receptor, Cannabinoid, CB1. Cited 9 times so far (Crossref); 102 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Agence Nationale de la Recherche, Université de Bourgogne, inversago pharma.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background and purpose Diabetic nephropathy (DN) is a common complication of diabetes. Current treatments include renin‐angiotensin‐aldosterone system (RAAS) blockers and sodium‐glucose co‐transporter 2 (SGLT2) inhibitors. The cannabinoid CB 1 receptor is a potential therapeutic target. We explored combining CB 1 receptor inverse agonism and SGLT2 inhibition for treating DN, to offer better reno‐protection. Experimental approach C57BLKS‐Lepr db/db and control mice were fed a high‐protein diet for 9 weeks. After 5 weeks, db/db mice were either exposed to placebo, empagliflozin (SGLT2 inhibitor), monlunabant (CB 1 receptor inverse agonist) or a combination of both compounds (same dose) by daily oral gavage for 28 days. Diagnostic parameters for DN were analysed, along with markers of oxidative stress, inflammation and renal fibrosis. Key results Both single treatments improved albuminuria and albumin‐to‐creatinine ratios, but the combination was more effective. Similar results were seen for inflammatory oxidative stress markers. The combination showed additive protective effects on glomerular morphology, podocyte loss and proximal tubular cell injury. Dual treatment significantly reduced tubulointerstitial fibrosis compared to monotherapy and vehicle‐treated mice. Transcriptomic analysis identified the STAT3 signalling pathway as a key mediator, with decreased STAT3 phosphorylation observed with both treatments. Key mediators involved included angiopoietin 1 and fibroblast growth factor 20, which modulated the STAT3 pathway via CB 1 receptors and SGLT2, respectively. Conclusions and implications Taken together, these data strongly suggest that a poly‐pharmacological approach combining both SGLT2 inhibitors and CB 1 receptor inverse agonism represents a promising therapeutic strategy for managing DN, with better reno‐protection than mono‐therapies.

Subjects

MeSH terms (MEDLINE)

Diabetic NephropathiesSodium-Glucose Transporter 2 InhibitorsReceptor, Cannabinoid, CB1AnimalsMice, Inbred C57BLMiceBenzhydryl CompoundsMaleGlucosidesDisease Models, AnimalFibrosisSodium-Glucose Transporter 2

Author keywords

CB1 receptorSGLT2STAT3diabetic nephropathyempagliflozinfibrosismonlunabant

Substances

Sodium-Glucose Transporter 2 InhibitorsReceptor, Cannabinoid, CB1Benzhydryl CompoundsempagliflozinGlucosidesSlc5a2 protein, mouseSodium-Glucose Transporter 2

Authors and institutions

  • Université Bourgogne Europe, INSERM, Center for Translation and Molecular medicine (CTM), Team PAthophysiology of DYSlipidemia (PADYS), Dijon, France.
  • Université Bourgogne Europe, INSERM, ImaFlow Corefacility, US58 BioSanD, Dijon, France.
  • Section on Fibrotic Disorders, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland, USA.
  • Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
  • INSERM 1155; Sorbonne University, Paris, France.
  • Division of Renal Transplantation, Hôpital Pitié-Salpétrière, Department of Nephrology, AP-HP, Paris, France.

ORCID profiles: Océane Pointeau, Sébastien Causse, Hélène François, Bruno Vergès, Pascal Degrace, Resat Cinar, Tony Jourdan

Funding

  • Agence Nationale de la Recherche
  • Université de Bourgogne
  • inversago pharma
  • European Regional Development Fund
  • Institut National de la Santé et de la Recherche Médicale
  • NIAAA NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism

Cite

APA

Pointeau, O., Ba, A. I., Geissler, A., Barbosa, R., Basu, A., Muhammad, A., Nivot, M., Loriot, M., Leemput, J., Passilly-Degrace, P., Causse, S., Demizieux, L., François, H., Vergès, B., Duan, J., Gaucher, G., Harvey, M., Degrace, P., Crater, G., …, & Jourdan, T. (2025). Blockade of cannabinoid CB 1 receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy. British Journal of Pharmacology, 182(21), 5355-5377. https://doi.org/10.1111/bph.70118

Vancouver

Pointeau O, Ba AI, Geissler A, Barbosa R, Basu A, Muhammad A, et al. Blockade of cannabinoid CB 1 receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy. British Journal of Pharmacology. 2025;182(21):5355-5377. doi:10.1111/bph.70118

BibTeX
@article{Pointeau2025,
  author = {Pointeau, Océane and Ba, Awa Isma and Geissler, Audrey and Barbosa, Romain and Basu, Abhishek and Muhammad, Arif and Nivot, Marina and Loriot, Maéva and Leemput, Julia and Passilly-Degrace, Patricia and Causse, Sébastien and Demizieux, Laurent and François, Hélène and Vergès, Bruno and Duan, Jianmin and Gaucher, Geneviève and Harvey, Michael and Degrace, Pascal and Crater, Glenn and Cinar, Resat and Jourdan, Tony},
  title = {Blockade of cannabinoid CB 1 receptors potentiates the anti‐fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {21},
  pages = {5355--5377},
  doi = {10.1111/bph.70118}
}
Start for free →